FSD Pharma has received FDA permission to design and submit an application for a new trial using a synthetic cannabinoid-based drug in the treatment of COVID-19.

AlphaMind Brands Inc is entering the functional mushrooms market.

MindMed has high hopes for its new LSD-based anxiety therapy.

MindMed’s Microdosing Division is expanding its ADHD clinical trial.

The California Department of Tax and Fee Administration (CDTFA) reported revenue numbers for cannabis sales for the 1st Quarter of 2020.

Numinus adds to its management team.

A recent study published in the journal Pain found that CBD treatment for dogs with osteoarthritis was beneficial in 9 out of 10 cases.

Many studies have suggested that cannabis is an effective treatment for neuropathic pain.

The Red Lake Nation in Minnesota has approved sweeping medical cannabis reforms that establish a program much more lenient and inclusive than the state program.

The busy Canadian company will fork over at least $40 million for a U.S.-based CBD company.